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INTRODUCTION 
 
Bladder cancer (BLCA) is one of the common 
malignant tumors in the human population, and has a 
frequency ranking of 10th amongst the catalog of all 
malignant tumors worldwide [1]. BLCA is also the 
second most common malignant tumor found 
associated with the urinary system [2]. New BLCA 
cases worldwide accounts for 3% of total cancers with 
mortality accounting for 2.1% of total cancer-related 
deaths [1]. 2018 American Cancer Society statistics 
revealed over 1.7 million new cancer cases, with over 
80 000 BLCA cases thus showing a high incidence of 
this disease state [3]. Notably, the pathophysiological 
properties of BLCA disease are exemplified by 
significantly increased metastasis, linked to the higher 
mortality rate. Conventional BLCA disease therapy 
combines both chemotherapy adjuvant and surgical 
resection of the tumor. In spite of such radical and 
invasive therapies, BLCA patient median survival time 
is ~15 months, with a relatively low 5 year survival 
rate of ~15% [4, 5]. There is thus an urgent need to 
identify new and more reliable disease-linked 
biomarkers to stratify BLCA patients into well-defined 
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Bladder cancer (BLCA) is one of the common malignant tumors of the urinary system. The poor prognosis of 
BLCA patients is due to the lack of early diagnosis and disease recurrence after treatment. Increasing evidence 
suggests that gene products of the nuclear factor of activated T-cells (NFAT) family are involved in BLCA 
progression and subsequent interaction(s) with immune surveillance. In this study, we carried out a pan-cancer 
analysis of the NFAT family and found that NFAT2 is an independent prognostic factor for BLCA. We then 
screened for differentially expressed genes (DEGs) and further analyzed such candidate gene loci using gene 
ontology enrichment to curate the KEGG database. We then used Lasso and multivariate Cox regression to 
identify 4 gene loci (FER1L4, RNF128, EPHB6, and FN1) which were screened together with NFAT2 to construct a 
prognostic model based on using Kaplan-Meier analysis to predict the overall survival of BLCA patients. 
Moreover, the accuracy of our proposed model is supported by deposited datasets in the Gene Expression 
Omnibus (GEO) database. Finally, a nomogram of this prognosis model for BLCA was established which could 
help to provide better disease management and treatment. 
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risk groups to enable better disease management and 
treatment. 
 
The first member of the nuclear factor of the activated  
T-cells (NFAT) family was discovered when T 
lymphocytes were stimulated by antigens to activate gene 
transcription leading to new cytokine synthesis of e.g. 
interleukin-2 [6]. Simultaneously, Feske and colleagues 
found that the activation of immune cells causes a rise in 
cytosolic calcium ion levels which cause NFAT 
activation in vivo, promoting the subsequent immune 
response to pathogen infection [7]. Surprisingly, recent 
studies suggest that NFAT family members can regulate 
cancer development and metastasis. In melanoma cells, 
NFAT2 and NFAT4 are activated by B-RAF-V600E via 
the canonical MAPK signal transduction pathway to 
promote COX-2 gene expression [8]. Increased COX-2 
expression is associated with poor prognosis in cancer 
[8]. In breast and colon cancer, NFAT5 can promote 
cancer invasion via the involvement of integrin α6β4 [9]. 
In breast cancer, NFAT activity promotes the invasion by 
stimulating COX-2 expression and prostaglandin 
synthesis [10]. Although NFAT family linkage to tumour 
development and progression was initially linked to 
cancer cell proliferation and migration, the prognostic 
value of NFAT activity in BLCA patients was unclear. 
 
Bioinformatics has become an increasing and widely 
used tool for tumor diagnosis, prognosis and prediction 
in cancer cases. Using a bioinformatics approach, 
Thakur and colleagues showed that transcriptomic 
signatures could have a prognostic value in melanoma 
[11]. In another study, screening a set of specific 
miRNAs using data deposited in The Cancer Genome 
Atlas (TCGA) database could be used to diagnose oral 
cancer; this conclusion was further supported from an 
analysis of the Gene Expression Omnibus (GEO) 
database within the National Center for Biotechnology 
Information (NCBI) [12]. Li and colleagues used 
clinical datasets in TCGA to assess the CpG island 
methylator phenotype (CIMP) in colorectal cancer and 
links to genomic aberrations and immune infiltration 
[13]. Meanwhile, the prognostic model using 4 genes 
was built to predict the overall survival (OS) of 
hepatocellular carcinoma (HCC) patients [13].  
 
In this study, we identified NFAT family expression in 
pan-cancer models using the TCGA database and 
genotype tissue expression (GTEx). We then combined 
LASSO regression and Cox regression analyses to build 
a predictive model for BLCA patient prognosis. A 5 
genes prognostic model was established which included 
NFAT2, FER1L4, RNF128, EPHB6 and FN1. This 
model was validated by analysis of different BLCA 
clinical datasets from multiple databases. This study 
supports the use of the NFAT family as a prognostic 
biomarker to help in BLCA stratification, disease 
management and therapy. 
 
MATERIALS AND METHODS 
 
Pan-cancer profiling for NFAT family gene expression 
 
To analyze gene expression profiles for the NFAT 
family of gene products in different malignant cancer, 
the GTEx, TCGA, and Oncomine databases were used. 
Oncomine is an online cancer microarray database 
(http://www.oncomine.org) [14] with a gene chip-based 
database and integrated data extraction platform. In this 
study, Oncomine was selected to compare the gene 
expression of NFAT family in tumors vs. normal tissues. 
The selection criteria for this study were “P<0.05, 
threshold: 2-fold change, gene rank: top 10%.” 
Meanwhile, the Gene Expression Profiling Interactive 
Analysis (GEPIA) tool was used to analyze the clinical 
datasets in the GTEx and TCGA databases to compare 
NFAT gene expression differences in pan-cancer models 
(http://gepia.cancer-pku.cn) [15]. 
 
Analysis of NFAT genetic alterations and expression 
profiling 
 
We utilized cBioPortal which is a visualization website 
integrating data from 126 tumor genome projects 
(http://www.cbioportal.org) [16]. We specified our 
query tumor type as “bladder urothelial carcinoma” and 
gene query names “NFAT1, NFAT2, NFAT3, NFAT4 
or NFAT4” were selected on the cBioPortal server. The 
NFAT mRNA expression levels were analyzed and 
Kaplan-Meier (KM) survival curves were generated to 
evaluate NFAT expression on overall survival (OS) and 
disease-free survival (DFS). 
 
Kaplan-Meier analysis  
 
To analyze BLCA prognostic values, R software with 
survival package was used to display OS. The P-value 
was calculated with values below 0.05 considered 
statistically significant. 
 
Analysis of differentially expressed genes (DEGs) 
 
The clinical data were extracted from the TCGA 
database and divided into high expression and low 
mRNA expression groups according to NFAT2 median 
expression. R software with limma, pheatmap, and 
ggplot2 packages was used to determine differential 
genes between the two groups. The 20 DEGs with the 
most significant up-regulation and down-regulation 
were displayed using volcanic and heat maps. 
Differential gene screening criteria | log FC | ≥2, 
P<0.05. 
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Analysis GO and KEGG pathway 
 
R software with clusterProfiler, DOSE and enrichplot 
packages was used to perform gene ontology (GO) 
functional analysis and Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathway analysis on the 
differential genes, and FDR<0.05 was set as a cut-off 
for significance [17–19]. 
 
Analysis of independent prognostic factor 
 
R software with survival and survminer packages was 
used to analyze TCGA clinical data. Both univariate 
analysis and multivariate analysis were used to generate 
Cox proportional hazard regression models. 
 
Protein-protein interaction analysis 
 
The top 100 DEGs were imported into the Search Tool 
for the Retrieval of Interacting Genes (STRING). This 
online tool facilitates building protein-protein interaction 
networks (PPI) (https://string-db.org) [20]. Results were 
also imported into Cytoscape software [21], and protein-
protein interaction networks and specific nodes within 
such networks were further analyzed using the MCODE 
tool in Cytoscape. The network scoring degree cutoff 
was 2 and the K-core was 2. 
 
Construction of risk score models  
 
First, the DEGs identified by limma were subjected to 
univariate Cox regression analysis. Second, a logistic 
regression model and the LASSO method for variable 
selection and shrinkage were applied to narrow the 
mRNA expression profiles by using R package glmnet 
4.0. The penalty regularization parameter k was 
determined via the cross-validation routine before 
running the main algorithm with an n-fold value equal 
to 10. The k value was finalized by using lambda min, 
which was the value of lambda, giving minimum mean 
cross-validated error [22]. Then, the data were 
randomly divided into training and testing sets. Finally, 
the multivariate Cox regression model was built. 
Besides, the model based on the training group was 
validated in the testing group by ROC and nomogram. 
Nomograms were widely applied to predict cancer 
patients’ prognoses, mainly because they could reduce 
the statistical prediction models into a single numerical 
assessment of the probability of OS that was tailored to 
the individual patient’s profile. In this study, the 
combined model based on all independent prognostic 
factors selected by the multivariable Cox regression 
analysis was used to construct a nomogram to assess the 
probability of 1-3-5 years OS for patients with BLCA. 
Subsequently, the nomogram’s calibration curve was 
evaluated graphically by plotting the nomogram 
prediction probabilities against the observed rates. 
Overlapping with the reference line demonstrated that 
the model was in perfect agreement. 
 
Analysis of GEO database 
 
We downloaded data from GSE13507 and GSE48276 in 
the GEO database in NCBI (http://www.ncbi.nlm.nih. 
gov/geo) [23]. This included data from 256 samples of 
bladder cancer tissue and adjacent tissues. GSE13507 is 
an expression profiling study with 165 primary bladder 
cancer samples, 23 recurrent non-muscle invasive tumor 
tissues, 58 normal-looking bladder mucosae surrounding 
cancer and 10 normal bladder mucosae analyzed using an 
Illumina human-6 v2.0 expression bead chip platform. R 
software was used to verify the risk model obtained by 
analysis of TCGA datasets. 
 
Analysis of immunohistochemistry expression 
 
The Human Protein Atlas (HPA) database is a large-scale 
protein research project, the main purpose of which is to 
map the positions of proteins encoded by expressed genes 
in human tissues and cells (https://www.proteinatlas.org) 
[24]. IHC data for potential clinical application was 
extracted from the HPA database in both normal tissue 
and bladder urothelial cancer, and results were shown as 
typical images. Such data validated the potential 





Human bladder cancer cell lines T24, 5637, and J82 
were obtained from the Cell Bank of Type Culture 
Collection (Chinese Academy of Sciences, Shanghai 
Institute of Cell Biology, Shanghai, P. R. China). Cell 
lines were maintained in RPMI1640 medium (GIBCO, 
Gaithersburg, MD, USA) supplemented with 10% fetal 
bovine serum (GIBCO). Cell lines were incubated at 
37° C in an atmosphere of 5% CO2 and 95% air. 
 
Colony formation assay 
 
200 cells per well were plated in 6-well plates. After 14 
days of culture in RPMI1640 medium, cells were fixed 
with 4% (w/v) paraformaldehyde, washed with PBS and 
stained with 0.1% (w/v) crystal violet. 
 
Cell proliferation assay 
 
Cell proliferation assays were performed using the Cell 
Counting Kit-8 (Donjindo, Japan). Cells were plated 
into 96-well plates in triplicate at approximately 2000 
cells per well and subjected to different treatment 
conditions. The OD value was measured using a 
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microplate reader (Thermo Fisher, Waltham, MA, 
USA) at a wavelength of 450 nm. 
 
Statistical analysis  
 
The data were presented as the mean ± standard 
deviation. Unpaired t-tests were used to compare the 
difference between two groups. P<0.05 was considered 
to indicate a statistically significant difference between 




NFAT family gene expression and genetic alterations 
in bladder cancer 
 
The expression of the mRNA expression levels 
corresponding to NFAT family members in BLCA 
patients was analyzed using the GTEx and TCGA 
database. The results showed that the NFAT family 
gene expression increased in the BLCA (Figure 1). To 
further determine the genetic alterations linked to such 
effects we used the cBioPortal database. Amongst the 
12 clinical datasets which were analyzed, the frequency 
of gene alterations, including mutations, amplifications, 
deep deletions, and multiple alterations, ranged from 
0.97% to 20.83%, with mutations and amplifications 
being the most observed alterations (Figure 2A). The % 
of genetic alterations within the NFAT family in BLCA 
varied from 3% to 5% for individual NFAT gene loci 
(Figure 2B). Meanwhile, clinical survival information 
was extracted to analyze the prognostic roles of the 
NFAT family in BLCA patients with or without 
alterations (Figure 2C). The results showed that the 
altered group had improved OS, but did not observe any 
significant correlation between the presence of 
alterations and DFS (Figure 2D). 
 
Prognostic value of NFAT family members in BLCA 
 
To further explore the prognostic value of each NFAT 
gene in BLCA, we used R software with a survival 
package to analyze the clinical BLCA datasets in the 
TCGA database. The results showed that after grouping 
BLCA patient overall survival (OS) based on the 
median value of gene expression, low NFAT2 
expression was strongly associated with the better or 
improved OS, whereas NFAT1, NFAT3, NFAT4, and 
NFAT5 expression were not related to OS in BLCA 
patients (Figure 3). 
 
Expression of NFAT2 in BLCA patients with 
different clinicopathological features 
 
Analysis of the clinical data extracted from TCGA 
found that the expression of NFAT2 had no relevance to 
the M stage, stage, gender, and age of the tumor (Figure 




Figure 1. The expression of NFAT family gene in BLCA. Blue represents the expression of normal tissues in the GTEx database, and red 
represents the expression of BLCA patients in the TCGA database. 
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difference, but there was no continuous significance 
from N0 to N4. It indicated that NFAT2 and N stage 
were not closely connected (Figure 4E). The same result 
also appeared in the T stage (Figure 4F). Surprisingly, 
in the classification of the BLCA tumor grades, NFAT2 
expression in high-grade groups was significantly 
higher than in low-grade groups (Figure 4G). 
 
NFAT2 is an independent prognostic risk factor for 
BLCA 
 
The information of BLCA patients with incomplete 
follow-up was removed from subsequent analyses. A 
Cox regression model for univariate analysis was used: 
we found that NFAT2 had no significant correlation 
with BLCA tumor stage and grade (Table 1). Moreover, 
the hazard ratio (HR) value was 1.113. In the TCGA 
database, the level characteristics of BLCA were only 
divided into high-grade and low-grade tumors. 
However, no deaths were recorded in BLCA patients 
with low-grade tumors. Surprisingly, multi-factor 
analysis using the Cox model found that NFAT2 could 
be used as an independent prognostic risk factor and 
was not affected by other factors (Figure 5). 
Screening for DEGs within BLCA patient groups 
with differential NFAT expression  
 
Our previous results demonstrated that NFAT2 
expression is linked to OS of BLCA patients. R software 
with the limma package was applied to screen DEGs of 
TCGA datasets focused on NFAT2 low vs. high 
expression groups in BLCA patients. A total of 1447 
DEGs were identified with 1153 up-regulated genes and 
294 down-regulated genes (Figure 6A). Furthermore, the 
top 20 up-regulated and down-regulated DEGs were 
plotted in a heatmap (Figure 6B). 
 
Biological analysis of DEGs between the high and 
low expression groups  
 
To assess DEG functionality, R software with the 
limma package was used to analyze all DEGs identified 
in BLCA. Our results showed that 2198 GO terms were 
enriched. The enrichment items were classified into 3 
functional groups: biological process (BP) group (1888 
items), cellular component (CC) group (137 items), and 
molecular function (MF) group (173 items). The top  




Figure 2. Genetic alterations of NFAT family genes. (A) Oncoprint visual summary of genetic alterations in NFAT family members.  
(B) Summary of genetic alterations in NFAT family members. (C) Kaplan-Meier survival curves for OS in cancer patients with genetic 
alterations. (D) Kaplan-Meier survival curves for DFS in cancer patients with genetic alterations. 
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for each item (Figure 7). Within the BP group, the top 3 
significant biological processes were leukocyte 
migration, regulation of lymphocyte activation, and 
phagocytosis. In the CC group, highlighted gene 
products were associated with the collagen-containing 
extracellular matrix, extracellular side of the plasma 
membrane, and immunoglobulins. Finally, the most 
enriched GO terms in the MF group are antigen 
binding, extracellular matrix structural constituent, and 
glycosaminoglycan binding.  
 
KEGG pathways were mainly enriched in cytokine-
cytokine receptor interaction, human T-cell leukemia 
virus 1 infection, MAPK signaling pathway, PI3K-Akt 
signaling pathway, and chemokine signaling pathway 
(Figure 8A). The pathway-pathway network showed the 
relationship between the 67 KEGG pathways enriched 
in all DEGs (Figure 8B). 
 
Protein-protein interaction (PPI) network analysis 
 
Protein-protein interaction (PPI) networks generated in 
silico help us to explore molecular mechanisms 
associated with specific gene products and biochemical 
pathways. The interactions among the identified top 100 
DEGs were analyzed by using the STRING database. 
The PPI network of the DEGs consisted of 72 nodes and 
533 edges (Figure 9A). Amongst these gene products, 
C1QA, C1QB, C1QC, COL1A1, and COL1A2 showed 
the highest combined score in PPI networks, suggesting 
that NFAT2 plays a key role in the immune system in 
BLCA. PPI network was imported into Cytoscape. The 
clusters by the MCODE app showed seven sub-
networks, and the sub-network with the highest score is 
shown in Figure 9B. Other sub-networks were shown in 
Table 2. These findings suggest that NFAT2 has a 
significant role cell function which could influence 
BLCA patient outcomes. 
 
Construction of overall survival risk score model for 
BLCA 
 
Based on our findings linking NFAT2 expression with 
BLCA patient overall survival (OS), and NFAT2 risk 
score model was built to predict BLCA patient survival. 




Figure 3. Prognostic value of NFAT members in BLCA patients. Kaplan-Meier survival curves for OS of BLCA patients with expression 
of NFAT1, NFAT2, NFAT3, NFAT4 and NFAT5. 
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correlation with NFAT2 in BLCA and we identified 8 
gene loci where the P-value was below 0.05. 
Furthermore, we used LASSO logistic regression 
combined with 10-fold cross-validation to narrow the 
mRNA expression profiles (Figure 10A, 10B). As a 
result, 5 gene loci were identified to build a predictive 
risk score model.  
 
The samples were randomly divided into training set and 
testing set, and the training set was used to obtain the 
model. The predictive model was characterized by the 
linear combination of the expression of these 5 genes 
weighted by their relative coefficient in the multivariate 
Cox regression as follows: risk score = (-0.262991181 * 
expression of FER1L4) + (0.235961475 * expression of 
RNF128) + (-0.180646092 * expression of EPHB6) + 
(0.097234847 * expression of FN1) + (0.084658888 * 
expression of NFAT2). 
 
The 204 patients of the testing set were used to validate 
the model in this study. The risk score was calculated, 




Figure 4. Expression of NFAT2 in BLCA patients with different clinical and pathological features. Kaplan-Meier survival curves for 
OS of BLCA patients and clinical factors. (A) M Stage. (B) Gender. (C) Age. (D) Stage. (E) N Stage. (F) T Stage. (G) Grade Stage. 
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Table 1. Univariate Cox proportional hazard model of the expression of NFAT2 and clinical factors. 
Univariate Cox analysis 
 HR HR.95L HR.95H pvalue 
age 1.041097238 1.02210766 1.06043962 1.80E-05 
gender 0.931539367 0.636464096 1.363416409 0.715185647 
grade 9617820.06 0 Inf 0.992093304 
stage 1.953870349 1.526479865 2.500923482 1.05E-07 
T 1.711736629 1.317903959 2.223259342 5.60E-05 
N 1.603321291 1.3433964 1.91353733 1.69E-07 
M 2.116864599 0.762125873 5.879758041 0.150207498 
NFAT2 1.113013537 1.027802607 1.205288958 0.008419016 
 
the risk score (Figure 10C). The K-M OS curves of the 
two groups, based on the 5 genes, were significantly 
different (Figure 10D). The prognostic capacity of the 
signatures for these 5 genes was assessed by calculating 
the AUC of a time-dependent ROC curve. The AUC of 
the prognostic model was 0.673 for the 1-year survival 
time. These results indicated that the forecast model had 




Figure 5. NFAT2 is an independent prognostic factor of BLCA. Multivariate Cox proportional hazard model of the expression of NFAT2 
and clinical factors. 
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Evaluation of the risk score model 
 
To establish a clinically applicable method for predicting 
the BLCA patients’ survival probability, a nomogram 
was built to predict the probability of the 1-3-5 years OS 
in the testing set (Figure 11A). The predictors of the 
nomogram included 5 factors. The 45° line represented 
the best prediction. Calibration plots showed that the 
nomogram performed well (Figure 11B). 
Validation of prognosis risk model 
 
To verify the prognostic value of NFAT2 and accuracy 
of the model for BLCA patients, we further analyzed 
other BLCA clinical expression datasets. Microarray 
data from clinical study GSE100926 in the GEO 
database was extracted and found significant differences 
in expression between BLCA cancer tissues and adjacent 




Figure 6. DEGs between high and low expression of NFAT2 groups. (A) Volcanic map for the DEGs identified by R software with 
limma package. The abscissa represented log2FC, and the ordinate represented the negative logarithm of the P-value. The red, green, and 
black nodes represented upregulated mRNA, downregulated mRNA, and non-differentially expressed mRNA. (B) Heatmap for the DEGs 
identified by R software with limma package. 
www.aging-us.com 10 AGING 
 
 
Figure 7. Gene ontology pathway enrichment analysis of DEGs. The rich factor demonstrates the degree of enrichment by GO. The 
node size represents the number of selected genes, and color represents the P-value of the enrichment analysis. CC, cellular component; MF, 
molecular function; BP, biological process. 
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levels were shown the same expression trend in the HPA 
database. Normal bladder tissue staining of NFAT2 
showed median expression in the nucleus (Figure 12G). 
However, in the cancer tissue samples, the NFAT2 
nuclear staining was significantly weaker than in normal 
tissue. According to the median value of NFAT2 nuclear 
expression as a classified condition, it was found that  




Figure 8. KEGG pathway enrichment analysis of DEGs. (A) The rich factor demonstrates the degree of enrichment by GO. The Node 
size represents the number of selected genes, and color represents the P-value of the enrichment analysis. (B) Network diagram provides the 
KEGG pathway interaction in the DEGs. 
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NFAT2 was better than that of the high-expression 
group, which indicated that the nuclear levels of NFAT2 
could affect the survival of BLCA patients (Figure 12A). 
Meanwhile, the prognostic model was assessed in the 
GEO data. A total of 165 patients in the GSE100926 
data were classified into a low-risk group and a high-risk 
group using the risk score mode. The result was 
consistent with the result in TCGA. The OS of the 
BLCA patients in the GSE100926 data in the high-risk 
group was significantly lower than that in the low-risk 
group (P<0.05) (Figure 12B). Furthermore, the AUCs of 
the external verification set were 0.643 at 1 year, 0.639 
at 2 years, and 0.664 at 3 years, demonstrating that this 
risk model can predict the OS of BLCA patients (Figure 
12C). The survival of patients was calculated based on 
the nomogram, and find that the nomogram performed 
well (Figure 12D, 12E). In order to further verify the 
accuracy of our model, using the same method with 
GSE48276 in the GEO database, the results also show 
that the model has a higher accuracy. The AUCs of 
GSE48276 was 0.643 at 1 year, 0.619 at 2 years, and 
0.622 at 3 years. 
 
NFAT2 has oncogenic function in BLCA 
 
In our previous studies it was found that in BLCA 
patients, the overall survival of the low expression group 
of NFAT2 was higher than that of the high expression 
group. We speculated that NFAT2 may function as an 
oncogene within the context of BLCA disease. We 
carried out cellular studies on three different BLCA cell 
lines, T24, J82, and 5637 (Figure 13). NFAT2 was 
expressed ~2-fold more in T24 vs. 5637 BLCA cell lines 
(Figure 13A, 13B). In the 5367 cell line, knockdown of 
NFAT2 expression using small hairpin RNA (sh-
NFAT2) using stable lentiviral transduction caused 
~80% reduction in NFAT2 levels (Figure 13C, 13D). 
NFAT2 knockdown caused ~60% reduction in 5637 cell 
proliferation (Figure 13E). The colony formation assay 
showed that knockdown of NFAT2 also caused a 
significant ~2-fold reduction in formation of the 5637 
cell colonies (Figure 13F). Incorporation of EdU 
nucleotide analog into genomic DNA to assess new 
DNA synthesis revealed similar findings on 5637  
cell proliferation (Figure 13G). Simultaneously, the 
Transwell cell migration assay showed revealed that 
NFAT2 knockdown inhibits the migratory and invasive 
capacity of 5637 cells (Figure 13H). The wounded cell 
monolayer assay experiment also showed that NFAT2 
knockdown caused ~2-fold decrease in cell migration 
(Figure 13I). Further analysis of control and NFAT2 
knockdown 5637 cells using immunoblotting showed a 
significant increase in E-cadherin and decrease in 
vimentin levels (Figure 13J). Quantification using qRT-
PCR in these 5637 cells revealed ~2-fold decrease in 
NFAT2 mRNA correlated with ~4-fold increase in E-
cadherin and ~4-fold decrease in vimentin mRNA levels 
(Figure 13K). Such findings link NFAT2 regulation of 
differential gene expression for E-cadherin and vimentin 
in BLCA development and progression. 
 
To further assess NFAT2 cancer functionality in vivo, 
the stably transfected 5637 cell line sh-NFAT2  




Figure 9. Network of protein-protein interactions (PPI) analysis. (A) Protein-protein interaction network was constructed for the 
DEGs using Cytoscape. (B) Subnetwork with the highest score using MCODE tool. 
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Table 2. The 6 sub networks significantly associated with the PPI of DEGs in patients with BLCA. 
Sub Network 
Cluster Score Nodes Edges Node IDs 
1 18.211 20 173 
MMP9, COL6A3, THBS2, CTHRC1, LUM, COL3A1, COL6A2, COL6A1, SFRP2, 
COMP, COL1A1, COL1A2, POSTN, NNMT, AEBP1, C1S, ISLR, DCN, SFRP4, FN1 
2 5.143 8 18 S100P, PSCA, TFF1, ERBB3, UPK2, AGR2, KRT7, MYCL 
3 4 4 6 C1QC, CHI3L1, C1QA, PTGDS 
4 3.333 4 5 KRT13, UPK1A, UPK3B, KRT20 
5 3 3 3 FOXA1, ID1, FGFR3 
6 2.8 6 7 LYZ, KRT19, KLF5, C1QB, CD14, TBX3 
 
subcutaneously into different groups of BALB/C 
immunodeficient Nude mice. This was carried out to 
determine whether NFAT2 expression influences 
BLCA tumor growth in vivo. Comparison of the control 
and NFAT2 knockdown mouse tumour groups was 
evaluated: knockdown of NFAT2 caused a significant 
~4-fold reduction in tumor weight (Figure 13L) and ~2-
fold reduction in tumor volume (Figure 13M). 
Immunohistochemical staining for the nuclear cell 
proliferation marker Ki-67 revealed that the NFAT2 
knockdown tumor group exhibited reduced staining 
compared to the control group (Figure 13N). Such 
findings suggest a strong link between NFAT2 





Bladder cancer (BLCA) is one of the most common 
cancers worldwide with an increasing incidence of 
bladder cancer annually. 70% of BLCA patients exhibit 
tumor metastases after cancer therapy, with a lifetime 
for follow-up and careful surveillance [25]. At present, 
BLCA clinical diagnostic methods rely mainly on 
cystoscopy and urine cytology. Cystoscopy is the gold 
standard for the BLCA diagnosis and follow-up. 
However, as cystoscopy is an invasive and expensive 
clinical technique, it is problematic for BLCA patients. 
Therefore, there is a need for BLCA biomarkers that 
have high sensitivity, high specificity, combined with 
rapid non-invasive diagnostic techniques. Common 
clinical BLCA biomarkers including urinary 
fibrinogen/fibrin degradation products (FB/FDP), 
bladder tumor antigen (BTA), nuclear matrix protein 22 
(NMP22), hyaluronic acid (HA), and hyaluronidase 
(Haase) [26–28] but these still lack accurate disease 
stratification for BLCA. Therefore, we urgently need to 
find BLCA biomarkers that are both predictive and can 
be used early in the disease process. This can help to 
improve the patient’s postoperative survival time. 
However, because the period of experimental 
verification is too long, new biomarkers discovery often 
takes a long time. The emergence of bioinformatics 
tools provides us with new ideas for discovering new 
BLCA biomarkers. 
 
NFAT was first discovered in T -cells as a 
transcriptional activator of the interleukin 2 [29, 30], and 
a key regulator of T-cell function in immune responses. 
Five NFAT family members, including NFAT1, 
NFAT2, NFAT3, NFAT4, and NFAT5 are often found 
to play a critical role in regulating the immune system 
and pro-inflammatory responses. For example, in a 
mouse model, NFAT activates transcription of the TNFα 
locus to promote autoimmune diseases such as 
rheumatoid arthritis, RA [31]. Deletion of the NFAT2 
gene locus inhibited mouse thymus development and the 
expression of anti-apoptotic protein BCL-2 [32]. 
However, increasing evidence shows a strong link 
between NFAT family members in tumor initiation, 
development and progression [8–10]. However, the link 
between NFAT expression in different cancer patients 
and link to disease development and progression was 
unclear. The emergence of cancer bioinformatics 
provides us with valuable tools for exploring NFAT 
expression in different cancers and patient outcomes. In 
our study, by integrating of cancers studies of datasets 
from GTEx, TCGA, and Oncomine databases, it was 
found that increased gene expression of NFAT family 
members correlated with increased incidence of BLCA. 
By analyzing cancer datasets using cBioPortal, it was 
found that the alterations within the gene loci encoding 
NFAT family members could also affect BLCA patient 
survival. Further analysis of clinical datasets in the 
TCGA database showed that OS for the NFAT2 low 
expression group was significantly higher than the 
NFAT2 high expression group. Multivariate analysis 
proves that the expression of NFAT2 was not affected 
by the characteristics of other cases. These findings 
suggested that NFAT2 might be an independent 
prognostic risk factor for BLCA diagnosis. R software 
was used to analyze the function of differential genes 
between high and low NFAT2 expression groups and 
construct corresponding interaction networks. It was 
found that a total of 2198 GO terms, 67 KEGG terms, 
and 6 sub-networks were enriched. Enrichment into the 
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PI3K-Akt signaling pathway via KEGG was the same as 
the previous research results. Kim and colleagues have 
previously shown that nerve growth factor activation of 
phosphatidylinositol 3-kinase: Akt: glycogen synthase 
kinase 3β pathway regulates NFAT expression in 
neurons [33]. Besides, genes in this sub-network are 
closely linked to the regulation of cell migration. Li and 




Figure 10. Construction of overall survival risk score model. (A) LASSO coefficient profiles of the genes associated with the DEGs.  
(B) Partial likelihood deviance was plotted versus log (Lambda). The vertical dotted line indicates the lambda value with the minimum error 
and the largest lambda value. (C) Risk scores of the patients in the high (red) and low (green) risk groups. (D) Patients of the validation set 
from TCGA were divided by risk score into high risk and a low risk groups. OS between two risk groups were analyzed and compared by 
Kaplan-Meier analysis. Red lines represent the high-risk group samples, and blue lines represent the low-risk group samples. (E) ROC curves in 
the validation set. The abscissa represents sensitivity, and the ordinate represents specificity. 
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knockdown inhibits cell proliferation and migration [34]. 
These independent studies further support our hypothesis 
that NFAT2 promotes BLCA cell migration and 
proliferation. It is also likely that NFAT2 is involved in 
other cellular pathways that contribute to cancer 
development and progression. 
 
An earlier study by Gyorffy and colleagues analyzed 
clinical datasets from non-small cell lung cancer in the 
TCGA database using univariate and multivariate Cox 
regression analysis, Kaplan-Meier analyses, and found 
that the expression of CDKN2A, OPN, EZH2, ANXA3, 
ADAM28 and ERCC1 genes significantly correlated 
with OS [35]. In recent studies, bioinformatics has been 
widely used to discover biomarkers and the construction 
of OS and DFS models. Yoshie and colleagues found 
that in prostate adenocarcinoma (PACA) patients, 
overexpression of PEG10 is linked to a reduction in 
PACA patient survival [36]. Another study revealed that 
the hyaluronic acid family could be used as a BLCA 
biomarker, whose expression positively correlated with 
transcriptional regulators such as β-catenin, Twist, and 
Snail expression levels [37]. In BLCA, patients have a 
poor prognosis due to the lack of reliable monitoring 
methods. Therefore, using a reliable prognostic model 
could help BLCA patients to status better. The use of 
cancer bioinformatics to build survival models based on 
multiple gene expression profiles to predict patient 
survival has been widely accepted and increasingly 
applied to diverse cancer disease states. Here, we 
constructed a prognostic risk assessment model based on 
multiple genes as a basis for clinical treatment. Unlike 
previous studies, this study not only randomized the 
original samples, but also identified genes related to 
prognosis based on an independent prognostic factor 
NFAT2. Univariate Cox, Lasso and multivariate Cox 
analyses were conducted to build a risk model to predict 
risk of BLCA prognosis. FER1L4, RNF128, EPHB6, 





Figure 11. Evaluation of risk score model. (A) The nomogram is applied by adding up the points identified on the points scale for each 
variable. (B) The calibration curve for predicting 1‐3-5 years OS for patients with BLCA. The Y‐axis represents actual survival, as measured by 
K‐M analysis, and the X‐axis represents the nomogram‐predicted survival (P<0.05). 
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For RNF128, the RING finger protein belongs to a subset 
(RNF subfamily) of the E3 ubiquitin ligase superfamily 
which facilitates the attachment of ubiquitin and 
ubiquitin-like proteins to target substrates [38, 39]. More 
than 200 RNF family members have been identified with 
diverse properties [40]. Several RNF family members 
have been implicated in cancer development [41–43]. 
RNF128 (also known as Grail), as a member of the RNF 
family, was first discovered as an E3 ubiquitin ligase, 
which was involved in regulating cellular immune 
function [44]. However, recent studies suggest that 
RNF128 plays an essential role in tumor occurrence and 
development. RNF128 is proposed to ubiquitinate p53 
and TBK1 to down-regulate tumor suppressor function 
and thus promote human leukemia development [45]. In 
esophageal squamous cell carcinoma, the overexpression 
of RNF128 promotes signaling through the EGFR/ 
MAPK/MMP-2 pathway to enhance cell invasion  
and metastasis [46]. In melanoma, down-regulation of 
RNF128 is proposed to activate Wnt/β-catenin signaling, 
which promotes higher epithelial-mesenchymal transition 
(EMT) and cell stemness [47]. RNF128 can also bind 
other E3 ubiquitin ligases, such as NEDD4, to promote 
the migration of lung cancer cells [45]. Our mining  
of the TCGA clinical database found that high  
RNF128 expression correlated with better BLCA patient 
prognosis. A model based on the expression of RNF128 
was constructed to predict the survival time of BLCA 
patients. 
 
The ephrin receptor, EphB6, functions as a tumor 
suppressor in cancer development [48–50]. In breast 
cancer, low EphB6 expression is linked to enhanced 
tumor invasiveness; treatment of aggressive breast cancer 
cell lines with 5’-aza-2’-deoxycytidine elevates EphB6 
expression and to reduces tumor cell invasiveness [48]. 
Hafner and colleagues studied melanomas and found that 
compared to benign moles, EphB6 mRNA expression 
decreased in melanoma and metastatic tumors [49]. 
Another study on colorectal cancer, found that decreased 
EphB6 expression correlated with decreased OS in 
cancer patients [50]. However, the link between EphB6 
and BLCA disease has not been fully explored. In our 
studies, the EphB6 low expression group exhibited 
reduced OS in BLCA disease. 
 
FER1L4 expression could inhibit colon cancer 




Figure 12. Validation of prognosis risk model. (A) Kaplan-Meier curves for OS time of patients with expression of NFAT2 in clinical study 
GSE100926. (B) Patients data from GSE100926 were divided by risk score into a high risk and a low risk groups. OS between two risk groups 
were analyzed and compared by Kaplan-Meier analysis. (C) 1-3-5 years ROC curves in GSE100926. The abscissa represents sensitivity, and the 
ordinate represents specificity. (D–F) The calibration curve for predicting 1-3-5 years OS for patients with BLCA. The Y-axis represents actual 
survival, as measured by K-M analysis, and the X-axis represents the nomogram‐predicted survival (P<0.05). (G) The expression profiles of the 
NFAT2 in the normal bladder tissue and bladder specimens. Images were taken from the HPA. 
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survival indicator in such patients [51]. Furthermore, 
FER1L4 inhibited the growth and invasion of 
esophageal squamous cell carcinoma cancer cells [52]. 
In endometrial cancer, FER1L4 acted as an independent 
prognostic indicator with the FER1L4 high expression 
group displayed markedly higher OS compared to the 
low FER1L4 expression group [53]. Combined with 
clinical information, we were found that the FER1L4 
high expression group of had better OS in BLCA. 
 
Fibronectin 1 (FN1) plays an essential role in cell-matrix 
and cell adhesion, cell migration, morphogenesis, 
differentiation, and carcinogenic transformation [54]. In 
breast and lung cancer, FN1 activated the PI3K/Akt 
signal transduction pathway by binding to the integrin 
receptor α5β1 [55, 56]. Han and colleagues found  
that FN1 stimulated non-small cell lung cancer cell 
proliferation by activating the mammalian target of 
rapamycin, mTOR [55]. Similarly, FN1 deletion during 
colorectal carcinogenesis could inhibit cell proliferation, 
migration, and invasion [57]. A number of studies have 
shown that miRNAs that target FN1 could modulate cell 
proliferation and invasion [58, 59]. Immunohistochemical 
analysis reporting elevated FN1 expression has been 
reported in various cancers, including breast, lung, 
thyroid and esophageal cancer [60–62]. These all 
indicated that the expression level of FN1 was closely 
linked to tumor initiation, development and progression. 
 
In terms of the effectiveness and stability assessment of 
the prognostic model, the AUC of the ROC curve of the 
internal verification set for the prognostic model for 
predicting the 1-year survival was 0.673. The AUCs of 




Figure 13. NFAT2 participates in the regulation of BLCA as an oncogene. (A) The expression of NFAT2 was verified by WB. (B) The 
expression of NFAT2 was verified by RT-PCR. (C) The knockdown efficiency was verified by RT-PCR. (D) The knockdown efficiency was verified 
by WB. (E) The cell viability was assessed by cell proliferation assay (see Materials and Methods). (F) Cell proliferation detected by colony 
formation assay. (G) Cell proliferation was measured by EdU incorporation assay. (H) Cell invasion measured by Transwell migration assay. (I) 
Cell migration evaluated by wounded cell monolayer closure assay. (J) Western Blot analysis of protein expression of NFAT2 and EMT-linked 
gene products. (K) Quantitative RT-PCR analysis of mRNA for NFAT2 and EMT-related genes. (L) Tumor weight from control and NFAT2 
knockdown mouse tumor groups. (M) Tumor volume from control and NFAT2 knockdown mouse tumor groups. (N) Tumor cell proliferation 
evaluated by Ki-67 immunohistochemical staining. *P<0.05; **P<0.01; ***P<0.001; #P<0.05. All data are representative of three independent 
experiments. 
www.aging-us.com 18 AGING 
1 year, 0.639 at 2 years, and 0.664 at 3 years. Analysis of 
each dataset shows that the high-risk BLCA group 
prognosis is worse than that of the low-risk BLCA group. 
A nomogram was further constructed to predict the OS of 
BLCA patients, and a calibration chart of the nomogram 
was drawn. These results showed that this model was a 
useful predictive model and could be used to predict the 
survival status of BLCA patients. However, our research 
also had specific limitations. First, the TCGA database is 
mainly composed of studies on Caucasians and people of 
African origin, and further ethnic group studies are 
required to verify our model. Secondly, our study was 
based on microarray data analysis. This was needed to 
extract a single gene to profile NFAT expression in 
cancer. The mechanism of NFAT2 action requires further 
studies using cell and animal models. 
 
Overall, our findings indicate the NFAT family 
expression is closely related to cancer initiation, 
development and/or progression. In the BLCA disease, 
NFAT2 can be used as an independent prognostic risk 
factor in assessing BLCA patient survival. Besides, the 
4-factor prognostic model based on NFAT2 was a 
reliable tool for predicting the OS of BLCA patients. 
The nomogram provided by this study could be a 
starting point to better develop personalized treatment 
plans for BCLA patients. 
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